Liberty Vision Presents LV Yttrium-90 Discs

We Have Developed an Yttrium-90 Episcleral Brachytherapy Source for Treatment of Ocular Tumors and Benign Growths.

Our mission is to bring advanced technology and methods to vision care, resulting in a better quality of life for patients and greater therapeutic value for physicians.

 

Innovations

Liberty Vision’s beta radiation discs and applicators are designed for ocular use. Our CEO and Chief Medical Officer, Paul T. Finger, MD, has spent decades researching and perfecting ophthalmic radiation devices through clinical research in collaboration with world-renowned medical physics and radiation experts. This knowledge has been used to perfect Liberty Vision’s Y-90 Disc radiation sources and its iWand® series of hand-held applicators. 

Safe and Effective Treatments 

Liberty Vision recognized the unmet potential to treat many eye diseases with radiation. This drove Liberty Vision to create and patent delivery systems that make application of brachytherapy straightforward, accurate, and easy to use.

Liberty Vision’s mission is to create the tools eye doctors need to deliver safe and effective radiation to maximize their patient outcomes.

Articles

Liberty Vision’s Y-90 Radiation System is not just for eye cancer

Liberty Vision’s Y-90 Radiation System is not just for eye cancer

Imagine that there was an ophthalmic tool that could quickly treat a wide range of eye conditions by custom-tuning the treatment dose to achieve the effect you wanted.  Liberty Vision has brought just such a tool to ophthalmic practice. It incorporates their...

“The 4-minute Plaque”

“The 4-minute Plaque”

We are excited to announce that the results from a procedure utilizing our iWand P and LV Y-90 Disc to treat choroidal melanoma will be presented as an abstract at The Retina Society 55th Annual meeting in November titled The...

Enter your Email for updates on our products!

Enter your Email for updates on our products!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!